Dianthus Therapeutics, Inc. /DE/

By person

33 insiders · 116 transactions

11.0×

Marino Garcia holds 11.0 times base salary in stock. $6.97M of shares against $630.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Marino Garcia last reported holding, valued at $106.74, the price Common Stock was last bought or sold at on the open market here, on 1 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Garcia Marino

CEO AND PRESIDENT

—

$27.96M (12) scheduled

−$27.96M

65,292

0.1167%

$6.97M

—

Savitz Ryan

EVP, CFO & CBO

—

$14.99M (14) scheduled

−$14.99M

0.0000%

$0.00

—

Randhawa Simrat

EVP, Head of R&D

$52.80K (2)

$15.00M (11) scheduled

−$14.95M

4,000

0.0072%

$426.96K

—

Booth Bruce

Director

$10.00M (1)

$254.42K (1)

+$9.75M

1,250,000

2.23%

$133.43M

—

Veness Adam M

SVP, General Counsel and Sec.

—

$4.63M (5) scheduled

−$4.63M

15,000

0.0268%

$1.60M

—

CARR EDWARD

CHIEF ACCOUNTING OFFICER

—

$3.56M (5) scheduled

−$3.56M

0.0000%

$0.00

—

Third Rock Ventures IV, L.P. entity

10% owner

—

$3.06M (2)

−$3.06M

3,058,204

5.47%

$326.43M

+3,061%

Soteropoulos Paula

Director

—

$2.25M (3) scheduled

−$2.25M

0.0000%

$0.00

—

GARDNER JASON

See Remarks

$6.00K (1)

$1.79M (8)

−$1.79M

651,964

1.17%

$69.59M

−3.3%

Fairmount Funds Management LLC entity

Director

$1.40M (5)

—

+$1.40M

0.0000%

$0.00

—

McGeorge Anne

Director

—

$844.82K (5) scheduled

−$844.82K

0.0000%

$0.00

—

COOKE MICHAEL P.

Chief Scientific Officer

—

$654.33K (14)

−$654.33K

240,523

0.4300%

$25.67M

−16.7%

Read Simon

Director

—

$630.79K (7) scheduled

−$630.79K

0.0000%

$0.00

—

DAVIS JOHN C. JR

See Remarks

—

$508.64K (4) scheduled

−$508.64K

8,304

0.0148%

$886.37K

—

ISACSON CHRISTINA K.

Chief Business Officer

—

$316.64K (3)

−$316.64K

83,786

0.1498%

$8.94M

−16.7%

Atlas Venture Fund X, L.P. entity

10% owner

—

$254.42K (1)

−$254.42K

3,148,399

5.63%

$336.06M

+3,154%

ZDRAVESKI ZORAN

See Remarks

—

$193.45K (2)

−$193.45K

128,009

0.2289%

$13.66M

−5.5%

Scadden David

Director

$99.00K (1)

—

+$99.00K

228,175

0.4079%

$24.36M

+17.9%

Deardorf Caren

Chief Commercial Officer

—

$41.98K (1)

−$41.98K

19,762

0.0353%

$2.11M

—

Beetham Thomas W.

See Remarks

—

$41.07K (1)

−$41.07K

19,897

0.0356%

$2.12M

—

Mahoney Stephen F.

See Remarks

—

$38.60K (1)

−$38.60K

17,264

0.0309%

$1.84M

—

Olson Lisa

See Remarks

—

$38.60K (1)

−$38.60K

14,264

0.0255%

$1.52M

—

Stants Kristen

Chief People Officer

—

$38.60K (1)

−$38.60K

20,264

0.0362%

$2.16M

—

Nichols David Wayne

Chief Technical Officer

—

$38.32K (1)

−$38.32K

14,306

0.0256%

$1.53M

—

Byers Blake

Director

—

3,339,137

5.97%

$356.42M

—

GV 2016 GP, L.L.C.

10% owner

—

3,339,137

5.97%

$356.42M

—

Meng Lei

Director

—

2,717,554

4.86%

$290.07M

+123.2%

MOULDER LEON O JR

Director

—

1,436,745

2.57%

$153.36M

+13.1%

RONNEBERG AMY L

Director

—

593,611

1.06%

$63.36M

—

BONNEY MICHAEL W

Director

—

215,346

0.3850%

$22.99M

+11.3%

Daniel Thomas O

Director

—

101,926

0.1822%

$10.88M

+31.7%

Albers Jeffrey W.

Director

—

4,152

0.0074%

$443.18K

—

Borisy Alexis

Director

—

4,100

0.0073%

$437.63K

—

Dianthus Therapeutics, Inc. /DE/

By person

Individual transactions

What was left out